ANK-302
/ Ankyra Therap
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
October 02, 2026
Safety and efficacy of ANK-302, an alum anchored CD28 and IL-2 bi-agonist in preclinical tumor models
(SITC 2026)
- No abstract available
Preclinical • Oncology • IL2
1 to 1
Of
1
Go to page
1